- Centers & Specialties
- Clinical Interests
- Non-Hodgkin's lymphoma (NHL)
- Hodgkin's lymphoma (also known as Hodgkin's disease)
- Chronic lymphocytic leukemia (CLL)
- Medical Education
- MD, Mount Sinai School of Medicine
- Residency, Massachusetts General Hospital
- Fellowship, Brigham and Women's Hospital|Fellowship, Dana Farber Cancer Institute
- Board Certifications
- Medical Oncology
- Boston: Massachusetts General Hospital
- Existing Patients
- Patient Gateway
- Insurances Accepted
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
Dr. Abramson is Director of the Lymphoma Program and the Jon and Jo Ann Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center. He is also Associate Professor of Medicine at Harvard Medical School. Dr. Abramson earned his medical degree from the Mount Sinai School of Medicine in New York City and a Masters Degree in Medical Sciences from Harvard Medical School. He completed a residency in Internal Medicine at the Massachusetts General Hospital in Boston, followed by a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. Dr. Abramson is board certified in Medical Oncology.
Dr. Abramson's clinical and research interests are in lymphoid malignancies, including all non-Hodgkin lymphomas, as well as Hodgkin lymphoma, and chronic lymphoid leukemias. His research involves identifying new targets for therapy in lymphomas and lymphoid leukemias, and the design and conduct of clinical trials of new cancer therapies and cellular immunotherapies in these diseases. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and a Fellow of the American College of Physicians. Dr. Abramson is the author of numerous papers and book chapters on lymphoma, and lectures widely.
- Research Summary
Dr. Abramson designs and conducts clinical trials of novel therapies and cellular immunotherapies including CAR T-cells for the treatment of non-Hodgkin lymphomas, Hodgkin lymphoma (Hodgkin's disease), and chronic lymphocytic leukemia (CLL).
- Abramson JS and Shipp MA. Advances in the biology, natural history and therapy of diffuse large B-cell lymphoma. Blood 2005.
- Abramson JS. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis and management. Oncologist 2006.
- Abramson JS, Chatterji M et al. A 51-year-old woman with splenomegaly and anemia. N Engl J Med 2008.
- Abramson JS, Chen W, et al. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br J Haem 2009.
- Abramson JS. Approach to the Patient with Lymphoma. In: Goroll AH and Mulley AG, editors. Primary Care Medicine 6th ed. LW&W 2009.
- Abramson JS, Digumarthy S et al. A 56-Year-Old Woman with Fever, Rash, and Lymphadenopathy. N Engl J Med 2009.
- Abramson JS and Scadden DT. Neoplasms in Acquired Immunodeficiency Syndrome. In: Kufe DW, et al. editors. Cancer Medicine 8. BC Decker 2010.
- Canellos GP, Abramson JS et al. Treatment of favorable, limited-stage Hodgkins lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 2010.
- Abramson JS, Hellmann M et al. Intravenous Methotrexate as CNS prophylaxis is associated with a low risk of CNS recurrence in high risk patients with Diffuse Large B Cell Lymphoma. Cancer 2010.
- Barnes JA. and Abramson JS. Evaluation of the addition of Ritiximab to CODOX-M/IVAC for Burkitt's Lymphoma. Ann Oncol 2011.
In a letter to the New England Journal of Medicine, a Massachusetts General Hospital (MGH) research team reports a remarkable treatment response in a patient participating in a clinical trial of a novel immune-system-based cancer therapy.
Making the students feel at ease in a large teaching hospital was the job of more than 75 MGH volunteers who hosted 100 students throughout the campus on Feb. 1 as part of the annual MGH Job Shadow Day, sponsored by the Center for Community Health Improvement.
55 Fruit Street
Yawkey Center for Outpatient Care
Boston, MA 02114-2696